Table 5.
Inhaled treatment during the 3-year study period, by categories of AFO
| Persistent AFO (n = 6550) | Variable AFO (n = 4507) | Absent AFO (n = 1434) | No spirometry (n = 1080) | Incomplete spirometry (n = 807) | |
|---|---|---|---|---|---|
| Short-acting bronchodilators n (%), median [IQR]a |
5410 (82.6) 8 [4, 10] |
3724 (82.6) 7 [4, 10] |
1055 (73.6) 6 [3, 9] |
368 (34.1) 5 [2, 9] |
628 (77.8) 8 [4, 10] |
| Long-acting bronchodilators n (%), median [IQR]a |
5017 (76.6) 10 [7, 10] |
3329 (73.9) 9 [6, 10] |
822 (57.3) 8 [5, 10] |
277 (25.6) 5 [2, 9] |
561 (69.5) 9 [6, 10] |
| Inhaled corticosteroids n (%), median [IQR]a |
4642 (70.9) 11 [7, 12] |
3168 (70.3) 10 [6, 12] |
862 (60.1) 9 [5, 12] |
300 (27.8) 6 [2, 10] |
503 (62.3) 10 [7, 12] |
| ICS/LABAb n (%), median [IQR]a |
4117 (62.9) 9 [6, 10] |
2703 (60.0) 8 [5, 10] |
657 (45.8) 7 [4, 10] |
230 (21.3) 5 [2, 8] |
438 (54.3) 9 [5, 10] |
| None of the above treatments, n (%) | 857 (13.1) | 540 (12.0) | 290 (20.2) | 672 (62.2) | 145 (18.0) |
Short-acting bronchodilators comprise short-acting beta2 agonists (SABA) and short-acting antimuscarinic bronchodilators (SAMA). Long-acting bronchodilators comprise long-acting beta2 agonists (LABA) and long-acting antimuscarinic bronchodilators (LAMA)
AFO airflow obstruction, ICS inhaled corticosteroids, IQR interquartile range
aNumber of patients receiving each class of medication and the number of 3-month periods (maximum of 12) in which ≥1 prescription was received
bIncludes patients receiving ICS/LABA in fixed combination inhalers or separately